The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: An update

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 1, 2008, Pages 86-96

  Prechel, Margaret ^a   Walenga, Jeanine M ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibody; Assays; Heparin; Thrombin inhibitor; Thrombocytopenia

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; ANTIBODY; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; APROTININ; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DANAPAROID; DEXTRAN; ERYTHROPOIETIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; GENERIC DRUG; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; HIRULOG; IDRAPARINUX; IMMUNOGLOBULIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; RECOMBINANT THROMBOMODULIN; RIVAROXABAN; THROMBIN INHIBITOR; UNINDEXED DRUG; WARFARIN;

ANTIBODY PRODUCTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; LABORATORY DIAGNOSIS; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; MOLECULAR SIZE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ANTICOAGULANTS; CHONDROITIN SULFATES; DERMATAN SULFATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA; HEPARIN; HEPARITIN SULFATE; HIRUDINS; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; PLATELET FACTOR 4; PLATELET FUNCTION TESTS; RECOMBINANT PROTEINS; THROMBIN; THROMBOCYTOPENIA;

EID: 43149098755     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1066027     Document Type: Review

References (100)

1. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988;72:925-930
2. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-96
3. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-251
4. Maccarana M, Lindahl U. Model of interaction between platelet factor 4 and heparin. Glycobiology 1993;3:271-277
5. Mayo KH, Ilyina E, Roongta V, et al. Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding. Biochem J 1995;312:357-365
6. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182-187
7. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparimplatelet factor 4. Blood 1998;91:916-922
8. Visentin GP. Heparin-induced thrombocytopenia: molecular pathogenesis. Thromb Haemost 1999;82:448-456
9. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005;105:131-138
10. Visentin GP, Ford SE, Scott PJ, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93:81-88
11. Newman PM, Chong WJ. Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br J Haematol 1999;107:303-309
12. Amiral J, Marfaing-Koka M, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-416
13. Regnault V, deMaistre E, Carteaux J, Gruel Y, Nguyen P. Platelet activation induced by human antibodies to interleukin-8. Blood 2003;101:1419-1421
14. Walenga JM, Prechel MM, Jeske WP, Bakhos M. Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia. Curr Opin Pulm Med 2005;11:385-391
15. Fareed J, Bick RL, Rao G, et al. The immunogenic potential of generic versions of low-molecular weight heparins may not be the same as the branded products. Clin Appl Thromb Hemost 2008;14:5-7
16. Jeske WP, Walenga JM, Szatkowski E, et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997;88:271-281
17. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699
18. Walenga JM, Jeske WP, Prechel MM, Bakhos M. Newer insights on the mechanism of heparin-induced thrombocytopenia. Semin Thromb Hemost 2004;30(Suppl 1):57-67
19. Jeske WP, Vasaiwala S, Schlenker R, Wallis E, Walenga JM. Leukocyte activation in heparin-induced thrombocytopenia. Blood 2000;96:29b
20. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97:3300-3302
21. Herbert JM, Savi P, Jeske WP, Walenga JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998;80:326-331
22. Walenga JM, Michal K, Hoppensteadt D, Wood JJ, Bick RL, Robinson JA. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost 1999;5(Suppl 1): S76-S84
23. Fareed J, Walenga JM, Hoppensteadt DA, et al. Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Semin Thromb Hemost 1999;25(Suppl 1):37-42
24. Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002;14:121-129
25. Matsuo T, Tomaru T, Kario K, Hirokawa T. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res 2005;115:475-481
26. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 2004;76:240-244
27. Reininger CB, Greinacher A, Graf J, Lassila R, Steckmeier B, Schwieberer L. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 1996;81:641-649
28. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-1708
29. Shuster TA, Silliman WR, Coats RD, Mureebe L, Silver D. Heparin-induced thrombocytopenia: twenty-nine years later. J Vasc Surg 2003;38:1316-1322
30. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004;126:311S-337S
31. Warkentin TE, Crowther MA. When is HIT really HIT? Ann Thorac Surg 2007;83:21-23
32. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-765
33. Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111:700-706
34. Parker RI. Measurement of heparin-dependent platelet antibodies in the diagnosis of heparin-induced thrombocytopenia: fact or fiction? Crit Care Med 2007;35:1784-1785
35. Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Bakhos M. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(Suppl. 1): 43-49
36. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69:344-350
37. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992;120:371-379
38. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999; 81:625-629
39. Izban KF, Lietz JW, Hoppensteadt DA, et al. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(Suppl 1):51-56
40. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 4th ed. New York, NY: Informa Healthcare; 2007:227-260
41. Martin-Toutain I, Piette JC, Diemert MC, Faucher C, Jobic L, Ankri A. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus 2007;16:79-83
42. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class to we need? J Lab Clin Med 2005;146:341-346
43. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patients samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006;76:420-426
44. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-96
45. Platelet Immunology ISTH Scientific Subcommittee. Chairs: Warkentin T, Chong B, Greinacher A, Gruel Y, Kiefel V, Kroll H. 6 July 2007. Palexpo, Geneva, Switzerland. Available at www.isth2007.com. Accessed December 6, 2007
46. Pouplard C, Gueret P, Fouassier M, Ternisien C, Trossaert M, Regina S. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007;5:1373-1379
47. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002;126:1415-1423
48. Zwicker JI, Uhl L, Huang W-Y, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004;2:2133-2137
49. Refaai MA, Laposata M, VanCott EM. Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia. Am J Clin Pathol 2003;119:61-65
50. Smythe MA, Koerber JM, Mattson JC. An evaluation of heparin platelet factor 4 antibody testing. J Thromb Haemost 2005;3(Suppl 1):1516
51. Messmore HL, Jeske WP, Wehrmacher W, Walenga JM. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Drug Safety 2003;26:625-641
52. Wallis DE, Workman DL, Lewis BF, Pifarré R, Moran JF. Failure of early heparin cessation as a treatment for heparin-induced thrombocytopenia. Am J Med 1999;106: 629-635
53. Lewis BE, Wallis DE, Berkowitz SD, et al. for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843
54. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. for the Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856
55. Greinacher A, Völpel H, Janssens U, et al. for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80
56. Greinacher A, Janssens U, Berg G, et al. for the HAT Investigataors. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593
57. Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999;25(Suppl 1):61-66
58. Walenga JM, Drenth AF, Mayuga M, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Clin Appl Thromb Hemost 2008; in press
59. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia. Arch Intern Med 2004;164:361-369
60. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003;110:73-82
61. Walenga JM, Fareed D, Schultz C, Neville B, Hoppensteadt D. Argatroban, not lepirudin or bivalirudin, treatment results in the generation of nitric oxide during parenteral administration. Blood 2004;104:512a
62. Lewis BE, Walenga JM, Hursting MJ. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Cardiovasc Rev Rep 2002;23:445-457
63. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329
64. Swan SK, St. Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20:756-770
65. La Monte MP, Brown PM, Hursting MJ. Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor. Expert Rev Cardiovasc Ther 2005;3:31-41
66. Matthai WH Jr, Hursting MJ, Lewis BE, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 2005;116: 121-126
67. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401-405
68. Lewis BE, Matthai WH, Cohen M, Moses J, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57: 177-184
69. Jang IK, Hurstings MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005;111:2671-2683
70. Cetta F, Graham LC, Wrona LL, Arruda MJ, Walenga JM. Argatroban use during pediatric interventional cardiac catheterization. Catheter Cardiovasc Interv 2004;61:147-149
71. Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004;18:31-37
72. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004;32:976-980
73. Cochran K, DeMartini TJ, Lewis BE, et al. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. J Invasive Cardiol 2003; 15:617-621
74. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Anti-hirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96:2373-2378
75. Greinacher A, Eichler P, Albrecht D, Strobel U, Potzsch B, Eriksson BI. Anti-hirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003;101:2617-2619
76. Fischer KG, Liebe V, Hudek R, et al. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost 2003;89:973-982
77. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT). Circulation 2003;108:2062-2065
78. Mahaffey KW, Lewis BE, Wildermann NMet alfor the ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of PCI in patients with heparin-induced thrombocytopenia (ATBAT) study. J Invasive Cardiol 2003;15:611-616
79. Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004;77:925-931
80. Koster A, Spiess B, Chew DP, et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 2004;93:356-359
81. Pötzsch B, Klovekorn WP. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000; 343:515-516
82. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006;95:967-981
83. Lindhoff-Last E, Kreutzenbeck H-J, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005;93:63-69
84. Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow Mfor the Australian HIT Study Group. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost 2001; 86:1170-1175
85. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001;85:950-957
86. Walenga JM, Koza MJ, Lewis BE, Pifarré R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996;2(Suppl 1):S21-S27
87. Elalamy I, Lecrubier C, Horellou MH, Conard J, Samama MM. Heparin-induced thrombocytopenia: laboratory management. Ann Med 2000;32(Suppl 1):60-67
88. Wallis DE, Quintos R, Wehrmacher W, Messmore HL. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest 1999;116:1333-1338
89. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004; 121:593-599
90. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435-440
91. Harder S, Graff J, Klinkhardt U, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on PT, aPTT, and ecarin clotting time. Thromb Haemost 2004;91:1137-1145
92. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2005;11:279-287
93. Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (Arixtra) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003;88: ECR32
94. D'Amico EA, Villaca PR, Gualandro SF, Bassitt RP, Chamone DA. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost 2003;1:2452-2453
95. Bradner J, Hallisey RK, Kuter DJ. Fondaparinux in the treatment of heparin-induced thrombocytopenia. Blood 2004;104: abstract 1775
96. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:2653-2655
97. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-3796
98. Walenga JM, Jeske WP, Wallis DE, et al. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost 1999;25(Suppl 1):77-81
99. Walenga JM, Lewis BE, Jeske WP, et al. Combined thrombin and platelet inhibition treatment for HIT patients. Haemostaseologie 1999;19:128-133
100. Haas S, Walenga JM, Jeske WP, Fareed J. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost 1999; 25(Suppl 1):67-75